| DESCRIPTION | - BRUNET et al., Nature, (19870000), vol. 328, pages 267 - 270 | - |
| DESCRIPTION | - CAMPOS-DA-PAZ et al., Mol. Biotechnol., (20080000), vol. 39, no. 2, pages 155 - 8 | - |
| DESCRIPTION | - CHAMBERS, Immunity, (19970000), vol. 7, pages 8855 - 8959 | - |
| DESCRIPTION | - EDGARROBERT C., Nucleic Acids Research, (20040000), vol. 32, page 1792 | - |
| DESCRIPTION | - GALON et al., Science, (20060000), vol. 313, pages 1960 - 1964 | - |
| DESCRIPTION | - GOUJON, Nucleic acids research, (20100000), vol. 38, pages W695 - 9 | - |
| DESCRIPTION | - GRABSTEIN et al., Science, (19940000), vol. 264, no. 5161, pages 965 - 968 | - |
| DESCRIPTION | - HORI et al., Blood, (19870000), vol. 70, no. 4, pages 1069 - 72 | - |
| DESCRIPTION | - KEARNEY, J. Immunol, (19950000), vol. 155, pages 1032 - 1036 | - |
| DESCRIPTION | - LEACH, Science, (19960000), vol. 271, pages 1734 - 1736 | - |
| DESCRIPTION | - NEDDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443 | - |
| DESCRIPTION | - PEARSONLIPMAN, Proc. Natl. Acd. Sci. USA, (19880000), vol. 85, page 2444 | - |
| DESCRIPTION | - QUEEN, Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, page 2869 | - |
| DESCRIPTION | - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327 | - |
| DESCRIPTION | - SMITHWATERMAN, Ad. App. Math., (19810000), vol. 2, page 482 | - |
| DESCRIPTION | - TILL et al., Proc. Natl. Acad. U.S.A., (19890000), vol. 86, no. 6, pages 1987 - 91 | - |
| DESCRIPTION | - WALUNAS et al., Immunity, (19940000), vol. 1, pages 405 - 413 | - |
| DESCRIPTION | - WEI et al., J. Immunol., (20010000), vol. 167, no. 1, pages 3598 - 282 | - |
| DESCRIPTION | - ZAGO et al., Biotechnol. Appl. Biochem., (20090000), vol. 52, pages 191 - 8 | - |
| OPPOSITION | - Anonymous, "CD20", Wikipedia, (20220327), Wikipedia, URL: https://en.wikipedia.org/w/index.php?title=CD20&oldid=1079562666, XP093197912 | - |
| OPPOSITION | - Anonymous, "Pidilizumab (CT-011)", CURETECH (accessed via the Wayback Machine), (20141004), CURETECH (accessed via the Wayback Machine), URL: https://web.archive.org/web/20141004072503/http://curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14, XP093239158 | - |
| OPPOSITION | - Anonymous, "Pidilizumab - CureTech", Adis Insight, (20231105), XP093211657 | - |
| OPPOSITION | - Anonymous, "Pidilizumab Overview", Creative Biolabs, (20240101), Creative Biolabs, URL: https://www.creativebiolabs.net/pidilizumab-overview.htm, XP093209607 | - |
| OPPOSITION | - Carroll John, "Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal1 cancer study", Fierce Biotech, (20160126), XP093197907 | - |
| OPPOSITION | - D29 - RLI sequence overview | - |
| OPPOSITION | - D36 - Declaration by inventor David Bechard | - |
| OPPOSITION | - D39 - Opposition Division’s decision for EP 3 030 575 | - |
| OPPOSITION | - D40 - Opposition Division’s decision for EP 3 444 271 | - |
| OPPOSITION | - D44 - Product Overview CureTech Website July 2017 | - |
| OPPOSITION | - D45 - pidilizumab _ Ligand page _ IUPHAR_BPS Guide to PHARMACOLOGY (no date found) | - |
| OPPOSITION | - Decision BOA T0025/24 | - |
| OPPOSITION | - Decision BOA T0419/16 | - |
| OPPOSITION | - expert declaration (Declaration of Prof. Dr. Roland Kontermann) | - |
| OPPOSITION | - HARDY B ET AL, "Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma.", International journal of oncology, Demetrios A. Spandidos Ed. & Pub, GR, GR , (20011101), vol. 19, no. 5, ISSN 1019-6439, pages 897 - 902, XP002400320 | - |
| OPPOSITION | - Lowe Derek, "Medivation Decides That Their Drug Isn't What They Thought", Science, (20160126), Science, URL: https://www.science.org/content/blog-post/medivation-decides-their-drug-isn-t-what-they-thought, XP093197901 | - |
| OPPOSITION | - "pidilizumab", PubChem, (20141113), Database accession no. SID 223366026, XP093197894 | - |
| OPPOSITION | - WEI X Q, ET AL, "The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo.", The Journal of Immunology, Williams & Wilkins Co., US, US , (20010701), vol. 167, no. 1, ISSN 0022-1767, pages 277 - 282, XP002394329 | - |
| OPPOSITION | - Marie Vincent, Anne Bessard, Denis Cochonneau, Géraldine Teppaz, Véronique Solé, Mike Maillasson, Stéphane Birklé, Laure Garrigue-Antar, Agnès Quéméner, Yannick Jacques, "Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency", International Journal of Cancer, Union Internationale Centre le Cancer., (20130801), vol. 133, no. 3, doi:10.1002/ijc.28059, ISSN 00207136, pages 757 - 765, XP055151554 | |
| OPPOSITION | - Ronald L. Schnaar et al., "Gangliosides as Siglec ligands", Glycoconjugate Journal, (2023), vol. 40, doi:10.1007/s10719-023-10101-2, XP093196624 | |
| OPPOSITION | - Crespo Joel, Sun Haoyu, Welling Theodore H, Tian Zhigang, Zou Weiping, "T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment", Current Opinion in Immunology, ELSEVIER, OXFORD., GB, GB , (20130401), vol. 25, no. 2, doi:10.1016/j.coi.2012.12.003, ISSN 0952-7915, pages 214 - 221, XP093211656 | |
| OPPOSITION | - Motz Greg t., Coukos George, "Deciphering and Reversing Tumor Immune Suppression", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20130701), vol. 39, no. 1, doi:10.1016/j.immuni.2013.07.005, ISSN 1074-7613, pages 61 - 73, XP055944165 | |
| OPPOSITION | - Ito, A. Handa, K. Withers, D.A. Satoh, M. Hakomori, S.-i., "Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression", FEBS Letters, ELSEVIER, AMSTERDAM., NL, NL , (20010601), vol. 498, no. 1, doi:10.1016/S0014-5793(01)02476-0, ISSN 0014-5793, pages 116 - 120, XP004243336 | |
| OPPOSITION | - Ira Mellman, George Coukos, Glenn Dranoff, "Cancer immunotherapy comes of age", Nature, ¬Macmillan Journals Ltd., etc.|, (20110101), vol. 480, no. 7378, doi:10.1038/nature10673, ISSN 00280836, pages 480 - 489, XP055054665 | |
| OPPOSITION | - Andrew M. Scott, Jedd D. Wolchok, Lloyd J. Old, "Antibody therapy of cancer", Nature Reviews Cancer, Nature Pub. Group, (20120101), vol. 12, no. 4, doi:10.1038/nrc3236, ISSN 1474175X, pages 278 - 287, XP055023837 | |
| OPPOSITION | - Ignacio Melero, David M. Berman, M. Angela Aznar, Alan J. Korman, José Luis Pérez Gracia, John Haanen, "Evolving synergistic combinations of targeted immunotherapies to combat cancer", Nature Reviews Cancer, Nature Pub. Group, London, London , vol. 15, no. 8, doi:10.1038/nrc3973, ISSN 1474-175X, pages 457 - 472, XP055316136 | |
| OPPOSITION | - EDWARDS J C W, ET AL., "EFFICACY OF B-CELL-TARGETED THERAPY WITH RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20040617), vol. 350, doi:10.1056/NEJMoa032534, ISSN 1533-4406, pages 2572 - 2581, XP008067127 | |
| OPPOSITION | - Ping Yu et al., "Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model", PNAS, (20120417), vol. 109, doi:10.1073/pnas.1203479109, XP055147800 | |
| OPPOSITION | - PETTIT D. K., ET AL., "STRUCTURE-FUNCTION STUDIES OF INTERLEUKIN 15 USING SITE-SPECIFIC MUTAGENESIS, POLYETHYLENE GLYCOL CONJUGATION, AND HOMOLOGY MODELING", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19970124), vol. 272., no. 04., doi:10.1074/jbc.272.4.2312, ISSN 0021-9258, pages 2312 - 2318., XP002042891 | |
| OPPOSITION | - BERNARD J, et al, "Identification of an interleukin-15alpha receptor-binding site on human interleukin-15.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20040604), vol. 279, no. 23, doi:10.1074/jbc.M312458200, ISSN 0021-9258, pages 24313 - 24322, XP002286785 | |
| OPPOSITION | - Erwan Mortier et al., "Soluble Interleukin-15 Receptor alpha (IL-15Ralpha)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rbeta/gamma", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20060120), vol. 281, doi:10.1074/jbc.M508624200, XP002394330 | |
| OPPOSITION | - Aline de Oliveira Albuquerque et al., "Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1", JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS, (2022), vol. 40, doi:10.1080/07391102.2021.1885492, XP093171502 | |
| OPPOSITION | - Chern Siang Lee, Mark Cragg, Martin Glennie, Peter Johnson, "Novel antibodies targeting immune regulatory checkpoints for cancer therapy", British Journal of Clinical Pharmacology, (20130801), vol. 76, no. 2, doi:10.1111/bcp.12164, ISSN 03065251, pages 233 - 247, XP055151740 | |
| OPPOSITION | - Chern Slang Lee et al., "Novel antibodies targeting immune regulatory checkpoints for cancer therapy", British Journal of Clinical Pharmacology, (2013), vol. 76, doi:10.1111/bcp.12164, XP071601266 | |
| OPPOSITION | - Ping Yu et al., "Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model", Clinical Cancer Research, (20101215), vol. 16, doi:10.1158/1078-0432.CCR-10-1966, XP055123618 | |
| OPPOSITION | - Wiliam E. Carson III, "Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy", Clinical Cancer Research, (2010), vol. 16, doi:10.1158/1078-0432.CCR-10-2658, XP055150942 | |
| OPPOSITION | - M. Sznol, L. Chen, "Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer", Clinical Cancer Research, Association for Cancer Research, (20130301), vol. 19, no. 5, doi:10.1158/1078-0432.CCR-12-2063, ISSN 10780432, pages 1021 - 1034, XP055123957 | |
| OPPOSITION | - Anne Bessard, Véronique Solé, Grégory Bouchaud, Agnès Quéméner, Yannick Jacques, "High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20090901), vol. 8, no. 9, doi:10.1158/1535-7163.MCT-09-0275, ISSN 1535-7163, pages 2736 - 2745, XP002636846 | |
| OPPOSITION | - Vanessa Kermer et al., "An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans-Presentation at the Tumor Site", Molecular Cancer Therapeutics, (2012), vol. 11, doi:10.1158/1535-7163.MCT-12-0019, XP002683666 | |
| OPPOSITION | - Kankana Bardhan, Theodora Anagnostou, Vassiliki A. Boussiotis, "The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation", Frontiers in Immunology, vol. 7, doi:10.3389/fimmu.2016.00550, XP055488786 | |
| OPPOSITION | - Menard Laurence C., Fischer Paul, Kakrecha Bijal, Linsley Peter S., Wambre Erik, Liu Maochang C., Rust Blake J., Lee Deborah, Penhallow Becky, Manjarrez Orduno Nataly, Nadler Steven G., "Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , (20181126), vol. 9, doi:10.3389/fimmu.2018.02728, ISSN 1664-3224, XP093209609 | |
| OPPOSITION | - Junker Fabian, Gordon John, Qureshi Omar, "Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation", Frontiers in Immunology, (20200101), vol. 11, doi:10.3389/fimmu.2020.01393, page 1393, XP055782877 | |
| OPPOSITION | - Philippova Julia, Shevchenko Julia, Sennikov Sergey, "GD2-targeting therapy: a comparative analysis of approaches and promising directions", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , vol. 15, doi:10.3389/fimmu.2024.1371345, ISSN 1664-3224, XP093196619 | |
| OPPOSITION | - Xiaoyun Zhu, Warren D. Marcus, Wenxin Xu, Hyung-Il Lee, Kaiping Han, Jack O. Egan, Jason L. Yovandich, Peter R. Rhode, Hing C. Wong, "Novel Human Interleukin-15 Agonists", The Journal of Immunology, Williams & Wilkins Co., US, US , (20090915), vol. 183, no. 6, doi:10.4049/jimmunol.0901244, ISSN 0022-1767, pages 3598 - 3607, XP055732478 | |
| OPPOSITION | - Miyazaki Keiko null, "Colonic Epithelial Cells Express Specific Ligands for Mucosal Macrophage Immunosuppressive Receptors Siglec-7 and -9", The Journal of Immunology, (2012), vol. 188, doi:10.4049/jimmunol.1100605, XP055948833 | |
| OPPOSITION | - Mélanie Desbois, Pauline Le Vu, Clélia Coutzac, Elie Marcheteau, Coralie Béal, Magali Terme, Alain Gey, Sébastien Morisseau, Géraldine Teppaz, Lisa Boselli, Yannick Jacques, David Béchard, Eric Tartour, Lydie Cassard, Nathalie Chaput, "IL-15 Trans -Signaling with the Superagonist RLI Promotes Effector/Memory CD8 + T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists", The Journal of Immunology, Williams & Wilkins Co., US, US , (20160701), vol. 197, no. 1, doi:10.4049/jimmunol.1600019, ISSN 0022-1767, pages 168 - 178, XP055442319 | |
| SEARCH | - JASON C STEEL ET AL, "Interleukin-15 biology and its therapeutic implications in cancer", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 33, no. 1, doi:10.1016/J.TIPS.2011.09.004, ISSN 0165-6147, (201201), pages 35 - 41, (20110930), XP028441944 [A] 1-7 * page 38, column 2, paragraph 3 * | |
| SEARCH | - W. E. CARSON, "Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy", CLINICAL CANCER RESEARCH, (20101029), vol. 16, no. 24, doi:10.1158/1078-0432.CCR-10-2658, ISSN 1078-0432, pages 5917 - 5919, XP055150942 [A] 1-7 * abstract; figure 1 * | |
